The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer - A pilot study

被引：41

作者：

Edler, David ^{[1
]}

Stenstedt, Kristina ^{[1
]}

Ohrling, Katarina ^{[2
]}

Hallstrom, Marja ^{[3
]}

Karlgren, Maria ^{[4
]}

Ingelman-Sundberg, Magnus ^{[4
]}

Raynhammar, Peter ^{[3
]}

机构：

[1] Karolinska Univ Hosp Solna, Dept Surg, S-17176 Stockholm, Sweden

[2] Karolinska Univ Hosp Solna, Dept Oncol, S-17176 Stockholm, Sweden

[3] Karolinska Univ Hosp Solna, CCK, S-17176 Stockholm, Sweden

[4] Karolinska Inst, Dept Physiol & Pharmacol, Pharmacogenet Sect, Stockholm 17177, Sweden

来源：

EUROPEAN JOURNAL OF CANCER | 2009年 / 45卷 / 04期

基金：

瑞典研究理事会;

关键词：

Colorectal cancer; Prognostic factor; CYP2W1; IHC; KIRSTEN RAS MUTATIONS; DNA METHYLATION; LYMPH-NODES; CYTOCHROME-P450; HYPOMETHYLATION; SURVIVAL; NUMBER; THERAPY; MARKERS; CELLS;

D O I：

10.1016/j.ejca.2008.11.031

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Cytochrome P450 (CYP) enzymes are important for drug metabolism. A novel cytochrome P450 enzyme, CYP2W1, has recently been identified. This enzyme is mainly found in foetal colon tissue and in tumour tissue. In this pilot study, we have investigated the expression of CYP2W1 in 162 tumours from patients with stages II and III colorectal cancer. Methods: The expression of CYP2W1 enzyme was immunohistochemically detected using a polyclonal antibody. Staining intensity was defined using a visual grading scale from 0 to 3. Grades 0-2 were classified as low, and grade 3 was classified as high expression of CYP2W1. Results: About 64% of the tumours expressed a low level of CYP2W1-expression, and 36% expressed a high level. CYP2W1-expression was an independent prognostic factor for overall survival (p = 0.007), where a high expression was associated with a worse clinical outcome. Conclusions: Immunohistochemically assessed expression of CYP2W1 is an independent prognostic factor in patients with stages II and III colorectal cancer. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：705 / 712

页数：8

共 33 条

[1] Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study [J].

Andreyev, HJN ;

Norman, AR ;

Cunningham, D ;

Oates, J ;

Dix, BR ;

Iacopetta, BJ ;

Young, J ;

Walsh, T ;

Ward, R ;

Hawkins, N ;

Beranek, M ;

Jandik, P ;

Benamouzig, R ;

Jullian, E ;

Laurent-Puig, P ;

Olschwang, S ;

Muller, O ;

Hoffmann, I ;

Rabes, HM ;

Zietz, C ;

Troungos, C ;

Valavanis, C ;

Yuen, ST ;

Ho, JWC ;

Croke, CT ;

O'Donoghue, DP ;

Giaretti, W ;

Rapallo, A ;

Russo, A ;

Bazan, V ;

Tanaka, M ;

Omura, K ;

Azuma, T ;

Ohkusa, T ;

Fujimori, T ;

Ono, Y ;

Pauly, M ;

Faber, C ;

Glaesener, R ;

de Goeij, AFPM ;

Arends, JW ;

Andersen, SN ;

Lövig, T ;

Breivik, J ;

Gaudernack, G ;

Clausen, OPF ;

De Angelis, P ;

Meling, GI ;

Rognum, TO ;

Smith, R .

BRITISH JOURNAL OF CANCER, 2001, 85 (05) :692-696

[2] Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study [J].

Andreyev, HJN ;

Norman, AR ;

Cunningham, D ;

Oates, JR ;

Clarke, PA .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (09) :675-684

[3] Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer [J].

Aung, PP ;

Oue, N ;

Mitani, Y ;

Nakayama, H ;

Yoshida, K ;

Noguchi, T ;

Bosserhoff, AK ;

Yasui, W .

ONCOGENE, 2006, 25 (17) :2546-2557

[4] Molecular events associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and K-ras oncogene activation [J].

Benbrahim-Tallaa, L ;

Waterland, RA ;

Styblo, M ;

Achanzar, WE ;

Webber, MM ;

Waalkes, MP .

TOXICOLOGY AND APPLIED PHARMACOLOGY, 2005, 206 (03) :288-298

[5] Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues [J].

Choudhary, D ;

Jansson, I ;

Stoilov, I ;

Sarfarazi, M ;

Schenkman, JB .

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2005, 436 (01) :50-61

[6] The number of analyzed lymph nodes -: a prognostic factor in colorectal cancer [J].

Edler, David ;

Ohrling, Katarina ;

Hallstrom, Marja ;

Karlberg, Mia ;

Ragnhammar, Peter .

ACTA ONCOLOGICA, 2007, 46 (07) :975-981

[7] DNA methylation in cancer: too much, but also too little [J].

Ehrlich, M .

ONCOGENE, 2002, 21 (35) :5400-5413

[8] Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer [J].

Frigola, J ;

Solé, X ;

Paz, MF ;

Moreno, V ;

Esteller, M ;

Capellà, G ;

Peinado, MA .

HUMAN MOLECULAR GENETICS, 2005, 14 (02) :319-326

[9] Will Rogers revisited: prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists [J].

George, S. ;

Primrose, J. ;

Talbot, R. ;

Smith, J. ;

Mullee, M. ;

Bailey, D. ;

du Boulay, C. ;

Jordan, H. .

BRITISH JOURNAL OF CANCER, 2006, 95 (07) :841-847

[10] Adjuvant chemotherapy in colorectal cancer:: A joint analysis of randomised trials by the Nordic gastrointestinal tumour adjuvant therapy group [J].

Glimelius, B ;

Dahl, O ;

Cedermark, B ;

Jakobsen, A ;

Bentzen, SM ;

Starkhammar, H ;

Grönberg, H ;

Hultborn, R ;

Albertsson, M ;

Påhlman, L ;

Tveit, KM .

ACTA ONCOLOGICA, 2005, 44 (08) :904-912

← 1 2 3 4 →